Snefix

Growth at reasonable price, macro
Snefix
Growth at reasonable price, macro
Contributor since: 2013
contrarian, growth at reasonable price, management change, cannabis stocks
Bio Insights, Contributor
special situations, micro-cap, biotech, healthcare
Chris DeMuth Jr., Contributor
value, event-driven, arbitrage, hedge fund manager
IPOdesktop, Contributor
value, IPOs, long only
Michelle Gilson, Contributor
Undergraduate, Tech stocks
Brad Thomas, Contributor
dividend growth investing, REITs, newsletter provider, value